Dr. Brain Secures Tens of Millions RMB in Series A+ Funding, Files for IPO

On March 15, Shanghai Yiwei Medical Technology Co., Ltd. (hereinafter referred to as “Dr. Brain”) announced the completion of its tens-of-millions-yuan Series A+ financing round, with China Venture Capital Fund serving as the sole investor in this round. Dr. Brain stated that the proceeds from this financing will be used to increase R&D investment in proprietary brain science technologies, enhance and enrich its AI-based diagnostic and therapeutic product portfolio focused on brain disorders, accelerate the dual deployment of core products in both hospital and health-checkup settings, and achieve comprehensive coverage of grassroots medical institutions through its “AI + Remote Brain Imaging Platform.” Over the past four years, Dr. Brain has successively secured investments from institutions including Daotong Investment, Haier Capital, and Beilu Pharmaceutical.

Since its establishment in 2017, Dr. Brain has remained committed to its original aspiration and vision of becoming a world-leading AI enterprise in brain imaging. The company has deeply cultivated proprietary technologies in brain science and neuroimaging, focusing on precision diagnosis and treatment solutions for neurodegenerative diseases represented by Alzheimer’s disease, and cerebrovascular diseases represented by stroke. It has successively launched China’s first AI-based precise brain structure analysis product, the “Dr. Brain Cloud Platform,” and “RuiNao,” a solution dedicated to precise preoperative assessment for stroke, both of which have obtained dual certification from the NMPA and CE. In terms of business expansion, Dr. Brain has been deployed in over 100 tertiary hospitals and has engaged in diversified product collaborations with institutions such as Meinian Onehealth, Ping An Insurance, Baoshihua Medical Group, and Yimai Yangguang. Using diagnosis as an entry point, the company is extending its services to early screening, preoperative assessment, and post-treatment rehabilitation, thereby creating a closed-loop business model covering the entire continuum of care for brain diseases.

Dr. Wang Silun, Co-founder and CEO of Dr. BrainHe stated, “Neuroscience is a crown jewel of the medical community. As brain specialists, we uphold the same reverence for medicine that I held when I first practiced as a physician. We remain deeply committed to addressing clinical needs and advancing the field of Chinese brain imaging. By leveraging the most advanced international AI imaging technologies, we strive to enhance the diagnosis and treatment of central nervous system disorders in China, aiming to provide healthcare professionals with specialized, diversified, and comprehensive full-cycle solutions.”

China currently has over 200 million patients with central nervous system disorders, including 50 million individuals suffering from dementia, such as Alzheimer’s disease. This burden generates annual public health expenditures exceeding RMB 100 billion. With the rapidly accelerating aging of the population, the number of people in China affected by cognitive disorders is expected to increase year by year. Dr. Wang Silun stated, “My research and professional background in neuroimaging over the past two decades have revealed that traditional diagnostic methods have led to extremely high rates of missed and misdiagnoses for cognitive disorders in clinical practice. In contrast, precision analysis and diagnosis based on neuroimaging represent a reliable and widely scalable technology in clinical settings, which will help significantly advance the window for accurate clinical judgment and improve diagnostic accuracy.” Leveraging its self-constructed largest brain imaging database in China, Dr. Brain launched the “Dr. Brain Cloud Platform” in 2018, the first product in China dedicated to precise analysis of brain structure. The platform has achieved high user stickiness among more than 100 tertiary hospitals. Furthermore, in collaboration with several leading health checkup institutions, Dr. Brain introduced the “Precision Brain Health Screening” program, filling a significant gap in the domestic health checkup market where routine in-depth brain examinations were previously unavailable.

In 2020, Dr. Brain further extended its product line to include AI-based diagnostic tools for cerebrovascular diseases, launching “RuiNao,” a solution dedicated to precise preoperative assessment of stroke, and an ASL (Arterial Spin Labeling) product focused on cerebrovascular disease screening. Stroke affects approximately 15 million people in China and is currently the leading cause of death, with a noticeable trend toward affecting younger populations in recent years. “We have partnered with top international research institutions and conducted multicenter studies with several major Grade A tertiary hospitals in China to develop an intelligent stroke solution. This aims to achieve precision and intelligence throughout the entire stroke diagnosis pathway, significantly improving the accuracy of preoperative assessments at hospital stroke centers. By leveraging cutting-edge international technology, we extend the therapeutic window for mechanical thrombectomy in ischemic stroke, gaining precious time for life-saving interventions,” added Dr. Wang Silun. “ASL (Arterial Spin Labeling) is currently the most advanced non-invasive MRI technique for measuring cerebral blood flow internationally. It can be widely applied in stroke screening, detection of neurodegenerative diseases, and brain tumor assessment. Dr. Brain collaborates closely with Johns Hopkins University and the ISMRM Perfusion Study Group to refine the standardization of ASL acquisition and processing techniques. We are committed to becoming the setter of ASL technical standards in China and providing customers with one-stop technical support. Currently, the ASL solution offered by Dr. Brain is the most advanced standardized solution globally.”

 Chen Zhanguo, Deputy General Manager of Luoying Huasheng Fund under China Venture Capital Fund, the sole investor in this roundIt stated: “Dr. Brain’s research in brain science and AI-based brain imaging analysis possesses exceptionally high technical barriers. Their brain imaging diagnostic products are of significant importance amid the macro trends of population aging and the intelligentization of imaging analysis. Furthermore, their multi-scenario commercial implementation has highlighted to the industry the diverse opportunities for AI imaging in clinical diagnosis, health screening, and insurance-based health management.”

Wang Xu, Chairman of Beilu Pharmaceutical“Since its establishment, Dr. Brain’s founding team has remained true to its original mission, dedicating itself to the precise diagnosis and treatment of cerebrovascular diseases. Through years of unwavering persistence, the company has not only expanded its product pipeline but also achieved breakthroughs in business development, creating a full-process commercial closed loop for brain disorders and paving the way for rapid growth. Beilu Pharmaceutical is honored to have witnessed this journey and will continue to support Dr. Brain as it moves forward. We look forward to fostering synergistic development with Dr. Brain in the future and achieving shared success.”

Cai Zhengyuan, CEO of Haier Capital“Haier Capital has consistently focused on cutting-edge technologies and industry trends in the early diagnosis of Alzheimer’s disease (AD) and innovative therapies. Dr. Brain’s AI-based imaging diagnostic technology leverages quantitative techniques to enable early screening and diagnosis before symptoms manifest, thereby helping to slow disease progression. This is precisely why Haier Capital chose Dr. Brain as a key investment in this sector. The participation of Zhongfeng Investment will further strengthen Dr. Brain’s competitive advantages in the industry. Haier Capital remains bullish on Dr. Brain and will continue to work with both new and existing shareholders to empower Dr. Brain to become a leader in the precision medicine field for central nervous system disorders, a market with a trillion-yuan scale.”

Sun Qi, Founding Managing Partner of Daotong Investmentstated: “As the earliest investor in Dr. Brain, we are delighted to see Dr. Wang and his team remain true to their original mission, achieving a series of advancements in brain science and neuroimaging. They have gradually established the largest standardized database based on Chinese brain models and built a precision diagnosis platform for central nervous system degenerative diseases and cerebrovascular diseases, represented by stroke. Dr. Brain is poised to become an essential tool for more neurologists and radiologists, helping more patients with early screening, early diagnosis, and early prevention and control of neurodegenerative diseases.”

China Venture Capital Fund (CVCF) is a professional investment institution specializing in venture capital and fund management. It was initiated by the Central Committee of the China Democratic National Construction Association (CDNCA) and established with equity participation from its members in 2000, making it one of the key pioneers of the domestic venture capital industry in China. CVCF has set up investment offices in more than ten cities, including Beijing, Shanghai, Shenzhen, Jinan, Shenyang, Qingdao, Wuhan, Changsha, Ningbo, Nantong, Yangzhou, and Changshu. The company currently manages dozens of RMB-denominated funds. Its investment scope covers angel investing, venture capital, private equity, and industrial M&A. Key investment sectors include energy conservation and environmental protection, new materials, new energy, high-end manufacturing, rail transit, military and aerospace, pharmaceuticals and healthcare, and the internet. To date, CVCF has invested in over 220 projects, helping dozens of portfolio companies list on domestic and international capital markets.

Beijing Beilu Pharmaceutical Co., Ltd. was established in September 1992. The Company is primarily engaged in the research and development, manufacturing, and sales of pharmaceutical products. It is recognized as a National High-Tech Enterprise and was among the first batch of companies listed on the ChiNext Board (Stock Code: 300016). The Company pioneered the development and launch of contrast media products in China. Through over two decades of industry exploration and professional accumulation, it has established unique core competitive advantages in this field, positioning itself as the leading enterprise in China’s contrast media industry. Additionally, the Company is intensifying its R&D efforts in central nervous system and endocrine therapeutics, striving to achieve product diversification.

Haier Capital, established in 2010 as the investment arm of Haier Financial Holdings, is positioned as an industrial ecosystem co-investment platform. It focuses on healthcare, intelligent technology, and innovative consumption, with business activities spanning venture capital, private equity, industrial M&A, and government-guided funds. As of 2020, it managed over RMB 19 billion in assets, striving to become a leading professional investment institution in China.

Daotong Investment focuses on early-stage investments and mergers and acquisitions in the healthcare industry, with investment areas including medical devices, healthcare services, biopharmaceuticals, and healthcare informatics. The core team of Daotong all come from the healthcare industry, possessing rich experience in corporate operations management, investment, and M&A. In the field of medical innovation technology, Daotong has made in-depth layouts. The Daotong investment team is highly stable, while also building a good investment ecosystem chain. Leveraging deep industry experience and resources, it provides strong post-investment support, creating high-value returns for partners.